Company Overview
About Future Fields
Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.
Business Model & Competitive Advantage
Future Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.
Competitive Landscape 2025–2026
In 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.
Recent Activity
View all →The post Resolving In-Vitro Diagnostic Supply Chain Constraints with the EntoEngine® appeared first on Future Fields .
Introduction The exponential growth of the global population has intensified the need to substantially increase agricultural production to ensure food security. At the same time, insect pests, weeds, and diseases are developing resistance to the control methods we have relied on to keep yields up and maintain crop quality. These needs, for more food that […] The post Biomanufacturing for Crop Traits Part 1: Understanding Expression Challenges for Plant-Incorporated Protectants (PIPs), Cry, Cyt, and Vip Insecticidal Proteins appeared first on Future Fields .
Foreign Filing filed 2026-08-20
Why Stability is Important for Scalability Most recombinant protein expression projects stall in the transition from pilot-scale discovery to large-scale manufacturing. While bench-scale transient methods can rapidly yield gram-level quantities for initial characterization, they present critical limitations at scale, such as plasmid loss and decreased expression that can compromise protein folding and biological activity. To […] The post Transgenic Fruit Flies vs. Cell Lines: Eliminating Bioreactor Bottlenecks appeared first on Future Fields .
The post Overcoming Crop Trait Protein Production Barriers with the EntoEngine® appeared first on Future Fields .
Key Differentiators
Emerging Innovator
Future Fields is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
S2
S2 is an AI-powered security platform focused on vulnerability discovery and attack surface management for enterprise security teams. The company's platform combines automated scanning, AI-powered ana
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Compare Future Fields with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Future Fields? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Future Fields Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Future Fields vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →